InsidersTradesSigma
Follow the KAMADA LTD share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €474.8m. The latest transaction was filed on 31 August 2026 (Retenue fiscale). Among the most active insiders: Brenner Yael. All data is free.
Analysts rate KAMADA LTD Strong Buy (bullish), based on 4 analysts. Average price target: US$13.50.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
6 of 6 declarations
Kamada Ltd is a biopharmaceutical company focused on the development and commercialization of therapeutic products based on proteins. It is listed on NASDAQ.